Platinum-Resistant Ovarian Cancer

An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers

Schedule an Appointment

Select an appointment date and time from available spots listed below.